Cisplatin Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting cisplatin clinical trials across 14 countries. Studies span Phase 2, Phase 3, Phase 1. Top locations include Nijmegen, Netherlands, Angers, France, Bangkok, Bangkoknoi, Thailand. Updated daily from ClinicalTrials.gov.


Cisplatin Trials at a Glance

8 actively recruiting trials for cisplatin are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Nijmegen, Angers, and Bangkok. Lead sponsors running cisplatin studies include AstraZeneca, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, and Acousia Therapeutics GmbH.

Browse cisplatin trials by phase

Treatments under study

About Cisplatin Clinical Trials

Looking for clinical trials for Cisplatin? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cisplatin trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cisplatin clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 3

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Phase 2

Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity

NephrotoxicityCisplatin Nephrotoxicity
Minia University50 enrolled1 locationNCT07564479
Recruiting
Phase 2

Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

Solid TumorsCisplatin Nephrotoxicity
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran46 enrolled1 locationNCT07018622
Recruiting
Phase 2

Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial

Sensorineural Hearing LossOtotoxicityOtotoxicity, Drug-Induced+1 more
Siriraj Hospital40 enrolled1 locationNCT07364747
Recruiting
Phase 3

Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial

Cisplatin-related Hearing Loss
The Netherlands Cancer Institute100 enrolled5 locationsNCT07281508
Recruiting
Phase 1Phase 2

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Platinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
TILT Biotherapeutics Ltd.29 enrolled3 locationsNCT05271318
Recruiting
Phase 2

ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin

Cisplatin-induced Hearing Loss
Acousia Therapeutics GmbH40 enrolled10 locationsNCT06521190
Recruiting
Phase 3

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

CisplatinCarboplatinNPC
Nanfang Hospital, Southern Medical University482 enrolled1 locationNCT03919552